顶部logo
顶部logo
more_1

home

ホーム > レポート一覧 > グローバル新規分子実体（NME）薬市場規模、主要企業シェア、ランキング分析レポート【2026年版】

グローバル新規分子実体（NME）薬市場規模、主要企業シェア、ランキング分析レポート【2026年版】

New Molecular Entity (NME) Drug - Global Top Players Market Share and Ranking 2026
  • レポートID：
    224164
  • 発表時期：
    2026-03-03
  • レポート形式：
    PDF
  • 産業カテゴリー：
    薬品及びサプリメント
  • レポート言語：
    英語、日本語
  • ページ数：
    124
  • 発行会社（調査会社）：
    YHResearch
title

言語とエディションの価格

  • 英語版
  • 日本語版
  • 英語と日本語版

個人版詳細

マルチユーザー版詳細

企業版詳細

  • 英語版
  • 日本語版
  • 英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.40円。

※米ドル表示価格+10％消費税。

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

title

レポートの概要

本報告書は、世界の新規分子実体（NME）薬市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。総販売数量、売上高、価格動向に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点から新規分子実体（NME）薬市場を分析し、需要構造と成長特性を明確化します。
新規分子実体（NME）薬市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における販売数量および売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、新規分子実体（NME）薬に関する的確な意思決定を行うための実践的なインサイトを提供します。
 主要新規分子実体（NME）薬市場の統計
2025年世界市場規模：百万米ドル
2026年世界市場規模：百万米ドル
2032年予測市場規模：百万米ドル
2026–2032年予測期間CAGR：
本レポートは新規分子実体（NME）薬市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。 
【市場セグメンテーション】
主要企業・競争環境
新規分子実体（NME）薬市場の主要企業には以下が含まれます：
UCB
Otsuka Pharmaceutical
Eli Lilly
Genentech
Eisai
Biogen
Menarini Group
GSK
Chest
Travere
Reata
Pfizer
Acadia Pharmaceuticals
Incyte
Cidara
Melinta
Pharming
LEO Pharma
Novartis
Argenx
Takeda
AbbVie
Bayer Hlthcare
Sanofi
Immumnocore 

製品別
Antibody
Polypeptide
Small Molecule Drug
Other 

アプリケーション別
Hospital
Clinic 

レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他

レポート構成（章別概要）
第1章｜市場概要と成長展望
新規分子実体（NME）薬市場の全体像を整理し、市場規模、売上予測、価格推移を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
新規分子実体（NME）薬市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、価格戦略、販売量、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別に新規分子実体（NME）薬市場を分類し、売上高、市場シェア、販売量、価格動向を分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別に新規分子実体（NME）薬市場規模、売上高、市場シェア、販売量、価格推移を整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、販売量、売上高を詳細に分析し、新規分子実体（NME）薬市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します
第6章｜国別市場動向
主要国・地域ごとに、新規分子実体（NME）薬市場の販売量、売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
新規分子実体（NME）薬市場を牽引する主要企業について、売上高、販売量、価格動向、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します

本レポートの要点と洞察
 新規分子実体（NME）薬市場の全体像と成長見通し
新規分子実体（NME）薬市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境が新規分子実体（NME）薬市場に与える影響を分析いたします
 市場環境の構成要素とマクロトレンド
新規分子実体（NME）薬産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略や価格形成に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します
 競争構造と主要企業の動向分析
新規分子実体（NME）薬市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します
 競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点から新規分子実体（NME）薬市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします
 成長要因・課題・リスクの分析
新規分子実体（NME）薬市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します
 将来トレンドと市場展望
新規分子実体（NME）薬市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします
title

Description

According to YH Research, the global market for New Molecular Entity (NME) Drug should grow from US$ million in 2025 to US$ million by 2032, with a CAGR of %for the period of 2026-2032.

New Molecular Entity refers to a chemical structure with certain biological activity. Due to its weak activity, low selectivity, poor absorption, or high toxicity, it cannot be directly used as medicine. However, as a new structural type and clue substance, through structural transformation and modification, drugs with excellent pharmacological effects can be obtained.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report studies and analyses global New Molecular Entity (NME) Drug status and future trends, to help determine the New Molecular Entity (NME) Drug market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for New Molecular Entity (NME) Drug, and provides market size (US$ million) and Year-over-Year growth, considering 2025 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global New Molecular Entity (NME) Drug market size, history data 2021-2025, and forecast data 2026 -2032, (US$ million)
(2) Global New Molecular Entity (NME) Drug by company, revenue, market share and industry ranking 2021-2026, (US$ million)
(3) Japan New Molecular Entity (NME) Drug by company, revenue, market share and industry ranking 2021-2026, (US$ million)
(4) Global New Molecular Entity (NME) Drug key consuming regions, consumption value and demand structure
(5) New Molecular Entity (NME) Drug industry chains, upstream, midstream and downstream
Market segment by players, this report covers
    UCB
    Otsuka Pharmaceutical
    Eli Lilly
    Genentech
    Eisai
    Biogen
    Menarini Group
    GSK
    Chest
    Travere
    Reata
    Pfizer
    Acadia Pharmaceuticals
    Incyte
    Cidara
    Melinta
    Pharming
    LEO Pharma
    Novartis
    Argenx
    Takeda
    AbbVie
    Bayer Hlthcare
    Sanofi
    Immumnocore

Market segment by Type, covers
    Antibody
    Polypeptide
    Small Molecule Drug
    Other

Market segment by Application, can be divided into
    Hospital
    Clinic

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe New Molecular Entity (NME) Drug product scope, global consumption value, Japan consumption value, development opportunities, challenges, trends, and policies
Chapter 2: Global New Molecular Entity (NME) Drug market share and ranking of major manufacturers, revenue, 2021-2026
Chapter 3: Japan New Molecular Entity (NME) Drug market share and ranking of major manufacturers, revenue, 2021-2026
Chapter 4: New Molecular Entity (NME) Drug industry chain, upstream, medium-stream, and downstream
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2021-2032
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2021-2032
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2021-2032
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2021-2032
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin
Chapter 10: Conclusions
title

Table of Contents

1 Market Overview
    1.1 New Molecular Entity (NME) Drug Definition
    1.2 Global New Molecular Entity (NME) Drug Market Size and Forecast
    1.3 Japan New Molecular Entity (NME) Drug Market Size and Forecast
    1.4 Share of Japan New Molecular Entity (NME) Drug Market with Respect to the Global Market
    1.5 New Molecular Entity (NME) Drug Market Size: Japan VS Global Growth Rate, 2021-2032
    1.6 New Molecular Entity (NME) Drug Market Dynamics
        1.6.1 New Molecular Entity (NME) Drug Market Drivers
        1.6.2 New Molecular Entity (NME) Drug Market Restraints
        1.6.3 New Molecular Entity (NME) Drug Industry Trends
        1.6.4 New Molecular Entity (NME) Drug Industry Policy
2 Global Leading Players and Market Share
    2.1 By Revenue of New Molecular Entity (NME) Drug, Global Market Share by Company, 2021-2026
    2.2 Global New Molecular Entity (NME) Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
    2.3 Global New Molecular Entity (NME) Drug Concentration Ratio
    2.4 Global New Molecular Entity (NME) Drug Mergers & Acquisitions, Expansion Plans
    2.5 Global New Molecular Entity (NME) Drug Major Companies Product Type
    2.6 Head Office and Area Served of Key Players
3 Japan Leading Players, Market Share and Ranking
    3.1 By Revenue of New Molecular Entity (NME) Drug, Japan Market Share by Company, 2021-2026
    3.2 Japan New Molecular Entity (NME) Drug New Molecular Entity (NME) Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Industry Chain Analysis
    4.1 New Molecular Entity (NME) Drug Industry Chain
    4.2 New Molecular Entity (NME) Drug Upstream Analysis
        4.2.1 New Molecular Entity (NME) Drug Core Raw Materials
        4.2.2 Main Manufacturers of New Molecular Entity (NME) Drug Core Raw Materials
    4.3 Midstream Analysis
    4.4 Downstream Analysis
    4.5 New Molecular Entity (NME) Drug Production Mode
    4.6 New Molecular Entity (NME) Drug Procurement Model
    4.7 New Molecular Entity (NME) Drug Industry Sales Model and Sales Channels
        4.7.1 New Molecular Entity (NME) Drug Sales Model
        4.7.2 New Molecular Entity (NME) Drug Typical Distributors
5 Sights by Type
    5.1 New Molecular Entity (NME) Drug Classification by Type
        5.1.1 Antibody
        5.1.2 Polypeptide
        5.1.3 Small Molecule Drug
        5.1.4 Other
    5.2 by Type, Global New Molecular Entity (NME) Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032
    5.3 by Type, Global New Molecular Entity (NME) Drug Consumption Value, 2021-2032
6 Sights by Application
    6.1 New Molecular Entity (NME) Drug Segment by Application
        6.1.1 Hospital
        6.1.2 Clinic
    6.2 by Application, Global New Molecular Entity (NME) Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032
    6.3 by Application, Global New Molecular Entity (NME) Drug Consumption Value, 2021-2032
7 Sales Sights by Region
    7.1 By Region, Global New Molecular Entity (NME) Drug Consumption Value, 2021 VS 2025 VS 2032
    7.2 By Region, Global New Molecular Entity (NME) Drug Consumption Value, 2021-2032
    7.3 North America
        7.3.1 North America New Molecular Entity (NME) Drug Market Size & Forecasts, 2021-2032
        7.3.2 By Country, North America New Molecular Entity (NME) Drug Market Size Market Share
    7.4 Europe
        7.4.1 Europe New Molecular Entity (NME) Drug Market Size & Forecasts, 2021-2032
        7.4.2 By Country, Europe New Molecular Entity (NME) Drug Market Size Market Share
    7.5 Asia Pacific
        7.5.1 Asia Pacific New Molecular Entity (NME) Drug Market Size & Forecasts, 2021-2032
        7.5.2 By Country/Region, Asia Pacific New Molecular Entity (NME) Drug Market Size Market Share
    7.6 South America
        7.6.1 South AmericaNew Molecular Entity (NME) Drug Market Size & Forecasts, 2021-2032
        7.6.2 By Country, South America New Molecular Entity (NME) Drug Market Size Market Share
    7.7 Middle East & Africa
8 Sales Sights by Country Level
    8.1 By Country, Global New Molecular Entity (NME) Drug Market Size & CAGR, 2021 VS 2025 VS 2032
    8.2 By Country, Global New Molecular Entity (NME) Drug Consumption Value, 2021-2032
    8.3 United States
        8.3.1 United States New Molecular Entity (NME) Drug Market Size, 2021-2032
        8.3.2 by Type, United States New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
        8.3.3 by Application, United States New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
    8.4 Europe
        8.4.1 Europe New Molecular Entity (NME) Drug Market Size, 2021-2032
        8.4.2 by Type, Europe New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
        8.4.3 by Application, Europe New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
    8.5 China
        8.5.1 China New Molecular Entity (NME) Drug Market Size, 2021-2032
        8.5.2 by Type, China New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
        8.5.3 by Application, China New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
    8.6 Japan
        8.6.1 Japan New Molecular Entity (NME) Drug Market Size, 2021-2032
        8.6.2 by Type, Japan New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
        8.6.3 by Application, Japan New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
    8.7 South Korea
        8.7.1 South Korea New Molecular Entity (NME) Drug Market Size, 2021-2032
        8.7.2 by Type, South Korea New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
        8.7.3 by Application, South Korea New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
    8.8 Southeast Asia
        8.8.1 Southeast Asia New Molecular Entity (NME) Drug Market Size, 2021-2032
        8.8.2 by Type, Southeast Asia New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
        8.8.3 by Application, Southeast Asia New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
    8.9 India
        8.9.1 India New Molecular Entity (NME) Drug Market Size, 2021-2032
        8.9.2 by Type, India New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
        8.9.3 by Application, India New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
    8.10 Middle East & Africa
        8.10.1 Middle East & Africa New Molecular Entity (NME) Drug Market Size, 2021-2032
        8.10.2 by Type, Middle East & Africa New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
        8.10.3 by Application, Middle East & Africa New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
9 Company Profile
    9.1 UCB
        9.1.1 UCB Company Information, Head Office, Market Area, and Industry Position
        9.1.2 UCB Company Profile and Main Business
        9.1.3 UCB New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.1.4 UCB New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.1.5 UCB Recent Developments
    9.2 Otsuka Pharmaceutical
        9.2.1 Otsuka Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
        9.2.2 Otsuka Pharmaceutical Company Profile and Main Business
        9.2.3 Otsuka Pharmaceutical New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.2.4 Otsuka Pharmaceutical New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.2.5 Otsuka Pharmaceutical Recent Developments
    9.3 Eli Lilly
        9.3.1 Eli Lilly Company Information, Head Office, Market Area, and Industry Position
        9.3.2 Eli Lilly Company Profile and Main Business
        9.3.3 Eli Lilly New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.3.4 Eli Lilly New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.3.5 Eli Lilly Recent Developments
    9.4 Genentech
        9.4.1 Genentech Company Information, Head Office, Market Area, and Industry Position
        9.4.2 Genentech Company Profile and Main Business
        9.4.3 Genentech New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.4.4 Genentech New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.4.5 Genentech Recent Developments
    9.5 Eisai
        9.5.1 Eisai Company Information, Head Office, Market Area, and Industry Position
        9.5.2 Eisai Company Profile and Main Business
        9.5.3 Eisai New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.5.4 Eisai New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.5.5 Eisai Recent Developments
    9.6 Biogen
        9.6.1 Biogen Company Information, Head Office, Market Area, and Industry Position
        9.6.2 Biogen Company Profile and Main Business
        9.6.3 Biogen New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.6.4 Biogen New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.6.5 Biogen Recent Developments
    9.7 Menarini Group
        9.7.1 Menarini Group Company Information, Head Office, Market Area, and Industry Position
        9.7.2 Menarini Group Company Profile and Main Business
        9.7.3 Menarini Group New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.7.4 Menarini Group New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.7.5 Menarini Group Recent Developments
    9.8 GSK
        9.8.1 GSK Company Information, Head Office, Market Area, and Industry Position
        9.8.2 GSK Company Profile and Main Business
        9.8.3 GSK New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.8.4 GSK New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.8.5 GSK Recent Developments
    9.9 Chest
        9.9.1 Chest Company Information, Head Office, Market Area, and Industry Position
        9.9.2 Chest Company Profile and Main Business
        9.9.3 Chest New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.9.4 Chest New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.9.5 Chest Recent Developments
    9.10 Travere
        9.10.1 Travere Company Information, Head Office, Market Area, and Industry Position
        9.10.2 Travere Company Profile and Main Business
        9.10.3 Travere New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.10.4 Travere New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.10.5 Travere Recent Developments
    9.11 Reata
        9.11.1 Reata Company Information, Head Office, Market Area, and Industry Position
        9.11.2 Reata Company Profile and Main Business
        9.11.3 Reata New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.11.4 Reata New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.11.5 Reata Recent Developments
    9.12 Pfizer
        9.12.1 Pfizer Company Information, Head Office, Market Area, and Industry Position
        9.12.2 Pfizer Company Profile and Main Business
        9.12.3 Pfizer New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.12.4 Pfizer New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.12.5 Pfizer Recent Developments
    9.13 Acadia Pharmaceuticals
        9.13.1 Acadia Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
        9.13.2 Acadia Pharmaceuticals Company Profile and Main Business
        9.13.3 Acadia Pharmaceuticals New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.13.4 Acadia Pharmaceuticals New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.13.5 Acadia Pharmaceuticals Recent Developments
    9.14 Incyte
        9.14.1 Incyte Company Information, Head Office, Market Area, and Industry Position
        9.14.2 Incyte Company Profile and Main Business
        9.14.3 Incyte New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.14.4 Incyte New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.14.5 Incyte Recent Developments
    9.15 Cidara
        9.15.1 Cidara Company Information, Head Office, Market Area, and Industry Position
        9.15.2 Cidara Company Profile and Main Business
        9.15.3 Cidara New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.15.4 Cidara New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.15.5 Cidara Recent Developments
    9.16 Melinta
        9.16.1 Melinta Company Information, Head Office, Market Area, and Industry Position
        9.16.2 Melinta Company Profile and Main Business
        9.16.3 Melinta New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.16.4 Melinta New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.16.5 Melinta Recent Developments
    9.17 Pharming
        9.17.1 Pharming Company Information, Head Office, Market Area, and Industry Position
        9.17.2 Pharming Company Profile and Main Business
        9.17.3 Pharming New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.17.4 Pharming New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.17.5 Pharming Recent Developments
    9.18 LEO Pharma
        9.18.1 LEO Pharma Company Information, Head Office, Market Area, and Industry Position
        9.18.2 LEO Pharma Company Profile and Main Business
        9.18.3 LEO Pharma New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.18.4 LEO Pharma New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.18.5 LEO Pharma Recent Developments
    9.19 Novartis
        9.19.1 Novartis Company Information, Head Office, Market Area, and Industry Position
        9.19.2 Novartis Company Profile and Main Business
        9.19.3 Novartis New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.19.4 Novartis New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.19.5 Novartis Recent Developments
    9.20 Argenx
        9.20.1 Argenx Company Information, Head Office, Market Area, and Industry Position
        9.20.2 Argenx Company Profile and Main Business
        9.20.3 Argenx New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.20.4 Argenx New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.20.5 Argenx Recent Developments
    9.21 Takeda
        9.21.1 Takeda Company Information, Head Office, Market Area, and Industry Position
        9.21.2 Takeda Company Profile and Main Business
        9.21.3 Takeda New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.21.4 Takeda New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.21.5 Takeda Recent Developments
    9.22 AbbVie
        9.22.1 AbbVie Company Information, Head Office, Market Area, and Industry Position
        9.22.2 AbbVie Company Profile and Main Business
        9.22.3 AbbVie New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.22.4 AbbVie New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.22.5 AbbVie Recent Developments
    9.23 Bayer Hlthcare
        9.23.1 Bayer Hlthcare Company Information, Head Office, Market Area, and Industry Position
        9.23.2 Bayer Hlthcare Company Profile and Main Business
        9.23.3 Bayer Hlthcare New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.23.4 Bayer Hlthcare New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.23.5 Bayer Hlthcare Recent Developments
    9.24 Sanofi
        9.24.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
        9.24.2 Sanofi Company Profile and Main Business
        9.24.3 Sanofi New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.24.4 Sanofi New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.24.5 Sanofi Recent Developments
    9.25 Immumnocore
        9.25.1 Immumnocore Company Information, Head Office, Market Area, and Industry Position
        9.25.2 Immumnocore Company Profile and Main Business
        9.25.3 Immumnocore New Molecular Entity (NME) Drug Models, Specifications, and Application
        9.25.4 Immumnocore New Molecular Entity (NME) Drug Revenue and Gross Margin, 2021-2026
        9.25.5 Immumnocore Recent Developments
10 Conclusion
11 Appendix
    11.1 Research Methodology
    11.2 Data Source
        11.2.1 Secondary Sources
        11.2.2 Primary Sources
    11.3 Market Estimation Model
    11.4 Disclaimer
title

Table of Figures

List of Tables
 Table 1. New Molecular Entity (NME) Drug Consumption Value & CAGR: Japan VS Global, 2021-2032, US$ Million
 Table 2. New Molecular Entity (NME) Drug Market Restraints
 Table 3. New Molecular Entity (NME) Drug Market Trends
 Table 4. New Molecular Entity (NME) Drug Industry Policy
 Table 5. Global New Molecular Entity (NME) Drug Revenue by Company, 2021-2026, US$ million, Ranked Based on Revenue in 2025
 Table 6. Global New Molecular Entity (NME) Drug Revenue Share by Company, 2021-2026, Ranked by Data of 2025
 Table 7. Global New Molecular Entity (NME) Drug Manufacturers Market Concentration Ratio (CR3 and HHI)
 Table 8. Global New Molecular Entity (NME) Drug Mergers & Acquisitions, Expansion Plans
 Table 9. Global New Molecular Entity (NME) Drug Major Companies Product Type
 Table 10. Head Office and Area Served of Key Players
 Table 11. Japan New Molecular Entity (NME) Drug Revenue by Company, 2021-2026, US$ million, Ranked Based on Revenue in 2025
 Table 12. Japan New Molecular Entity (NME) Drug Revenue Market Share by Company, 2021-2026
 Table 13. Global Key Players of New Molecular Entity (NME) Drug Upstream (Raw Materials)
 Table 14. Global New Molecular Entity (NME) Drug Typical Customers
 Table 15. New Molecular Entity (NME) Drug Typical Distributors
 Table 16. by Type, Global New Molecular Entity (NME) Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million
 Table 17. by Application, Global New Molecular Entity (NME) Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million
 Table 18. By Region, Global New Molecular Entity (NME) Drug Consumption Value, 2021 VS 2025 VS 2032, US$ Million
 Table 19. By Region, Global New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Table 20. By Country, Global New Molecular Entity (NME) Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million
 Table 21. By Country, Global New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Table 22. By Country, Global New Molecular Entity (NME) Drug Consumption Value Market Share, 2021-2032
 Table 23. UCB Company Information, Head Office, Market Area, and Industry Position
 Table 24. UCB Company Profile and Main Business
 Table 25. UCB New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 26. UCB New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 27. UCB Recent Developments
 Table 28. Otsuka Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
 Table 29. Otsuka Pharmaceutical Company Profile and Main Business
 Table 30. Otsuka Pharmaceutical New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 31. Otsuka Pharmaceutical New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 32. Otsuka Pharmaceutical Recent Developments
 Table 33. Eli Lilly Company Information, Head Office, Market Area, and Industry Position
 Table 34. Eli Lilly Company Profile and Main Business
 Table 35. Eli Lilly New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 36. Eli Lilly New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 37. Eli Lilly Recent Developments
 Table 38. Genentech Company Information, Head Office, Market Area, and Industry Position
 Table 39. Genentech Company Profile and Main Business
 Table 40. Genentech New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 41. Genentech New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 42. Genentech Recent Developments
 Table 43. Eisai Company Information, Head Office, Market Area, and Industry Position
 Table 44. Eisai Company Profile and Main Business
 Table 45. Eisai New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 46. Eisai New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 47. Eisai Recent Developments
 Table 48. Biogen Company Information, Head Office, Market Area, and Industry Position
 Table 49. Biogen Company Profile and Main Business
 Table 50. Biogen New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 51. Biogen New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 52. Biogen Recent Developments
 Table 53. Menarini Group Company Information, Head Office, Market Area, and Industry Position
 Table 54. Menarini Group Company Profile and Main Business
 Table 55. Menarini Group New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 56. Menarini Group New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 57. Menarini Group Recent Developments
 Table 58. GSK Company Information, Head Office, Market Area, and Industry Position
 Table 59. GSK Company Profile and Main Business
 Table 60. GSK New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 61. GSK New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 62. GSK Recent Developments
 Table 63. Chest Company Information, Head Office, Market Area, and Industry Position
 Table 64. Chest Company Profile and Main Business
 Table 65. Chest New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 66. Chest New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 67. Chest Recent Developments
 Table 68. Travere Company Information, Head Office, Market Area, and Industry Position
 Table 69. Travere Company Profile and Main Business
 Table 70. Travere New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 71. Travere New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 72. Travere Recent Developments
 Table 73. Reata Company Information, Head Office, Market Area, and Industry Position
 Table 74. Reata Company Profile and Main Business
 Table 75. Reata New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 76. Reata New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 77. Reata Recent Developments
 Table 78. Pfizer Company Information, Head Office, Market Area, and Industry Position
 Table 79. Pfizer Company Profile and Main Business
 Table 80. Pfizer New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 81. Pfizer New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 82. Pfizer Recent Developments
 Table 83. Acadia Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
 Table 84. Acadia Pharmaceuticals Company Profile and Main Business
 Table 85. Acadia Pharmaceuticals New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 86. Acadia Pharmaceuticals New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 87. Acadia Pharmaceuticals Recent Developments
 Table 88. Incyte Company Information, Head Office, Market Area, and Industry Position
 Table 89. Incyte Company Profile and Main Business
 Table 90. Incyte New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 91. Incyte New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 92. Incyte Recent Developments
 Table 93. Cidara Company Information, Head Office, Market Area, and Industry Position
 Table 94. Cidara Company Profile and Main Business
 Table 95. Cidara New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 96. Cidara New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 97. Cidara Recent Developments
 Table 98. Melinta Company Information, Head Office, Market Area, and Industry Position
 Table 99. Melinta Company Profile and Main Business
 Table 100. Melinta New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 101. Melinta New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 102. Melinta Recent Developments
 Table 103. Pharming Company Information, Head Office, Market Area, and Industry Position
 Table 104. Pharming Company Profile and Main Business
 Table 105. Pharming New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 106. Pharming New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 107. Pharming Recent Developments
 Table 108. LEO Pharma Company Information, Head Office, Market Area, and Industry Position
 Table 109. LEO Pharma Company Profile and Main Business
 Table 110. LEO Pharma New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 111. LEO Pharma New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 112. LEO Pharma Recent Developments
 Table 113. Novartis Company Information, Head Office, Market Area, and Industry Position
 Table 114. Novartis Company Profile and Main Business
 Table 115. Novartis New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 116. Novartis New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 117. Novartis Recent Developments
 Table 118. Argenx Company Information, Head Office, Market Area, and Industry Position
 Table 119. Argenx Company Profile and Main Business
 Table 120. Argenx New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 121. Argenx New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 122. Argenx Recent Developments
 Table 123. Takeda Company Information, Head Office, Market Area, and Industry Position
 Table 124. Takeda Company Profile and Main Business
 Table 125. Takeda New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 126. Takeda New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 127. Takeda Recent Developments
 Table 128. AbbVie Company Information, Head Office, Market Area, and Industry Position
 Table 129. AbbVie Company Profile and Main Business
 Table 130. AbbVie New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 131. AbbVie New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 132. AbbVie Recent Developments
 Table 133. Bayer Hlthcare Company Information, Head Office, Market Area, and Industry Position
 Table 134. Bayer Hlthcare Company Profile and Main Business
 Table 135. Bayer Hlthcare New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 136. Bayer Hlthcare New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 137. Bayer Hlthcare Recent Developments
 Table 138. Sanofi Company Information, Head Office, Market Area, and Industry Position
 Table 139. Sanofi Company Profile and Main Business
 Table 140. Sanofi New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 141. Sanofi New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 142. Sanofi Recent Developments
 Table 143. Immumnocore Company Information, Head Office, Market Area, and Industry Position
 Table 144. Immumnocore Company Profile and Main Business
 Table 145. Immumnocore New Molecular Entity (NME) Drug Models, Specifications, and Application
 Table 146. Immumnocore New Molecular Entity (NME) Drug Revenue and Gross Margin, US$ Million, 2021-2026
 Table 147. Immumnocore Recent Developments


List of Figures
 Figure 1. New Molecular Entity (NME) Drug Picture
 Figure 2. Global New Molecular Entity (NME) Drug Consumption Value, (US$ million) & (2021-2032)
 Figure 3. Japan New Molecular Entity (NME) Drug Consumption Value, (US$ million) & (2021-2032)
 Figure 4. By Consumption Value, Japan New Molecular Entity (NME) Drug Market Share of Global, 2021-2032
 Figure 5. Global New Molecular Entity (NME) Drug Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2025
 Figure 6. Japan New Molecular Entity (NME) Drug Key Participants, Market Share, 2025
 Figure 7. New Molecular Entity (NME) Drug Industry Chain
 Figure 8. New Molecular Entity (NME) Drug Procurement Model
 Figure 9. New Molecular Entity (NME) Drug Sales Model
 Figure 10. New Molecular Entity (NME) Drug Sales Channels, Direct Sales, and Distribution
 Figure 11. Antibody
 Figure 12. Polypeptide
 Figure 13. Small Molecule Drug
 Figure 14. Other
 Figure 15. by Type, Global New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 16. by Type, Global New Molecular Entity (NME) Drug Consumption Value Market Share, 2021-2032
 Figure 17. Hospital
 Figure 18. Clinic
 Figure 19. by Application, Global New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 20. by Application, Global New Molecular Entity (NME) Drug Revenue Market Share, 2021-2032
 Figure 21. By Region, Global New Molecular Entity (NME) Drug Consumption Value Market Share, 2021-2032
 Figure 22. North America New Molecular Entity (NME) Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 23. By Country, North America New Molecular Entity (NME) Drug Consumption Value Market Share, 2025
 Figure 24. Europe New Molecular Entity (NME) Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 25. By Country, Europe New Molecular Entity (NME) Drug Consumption Value Market Share, 2025
 Figure 26. Asia Pacific New Molecular Entity (NME) Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 27. By Country/Region, Asia Pacific New Molecular Entity (NME) Drug Consumption Value Market Share, 2025
 Figure 28. South America New Molecular Entity (NME) Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 29. By Country, South America New Molecular Entity (NME) Drug Consumption Value Market Share, 2025
 Figure 30. Middle East & Africa New Molecular Entity (NME) Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 31. United States New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 32. by Type, United States New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 33. by Application, United States New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 34. Europe New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 35. by Type, Europe New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 36. by Application, Europe New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 37. China New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 38. by Type, China New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 39. by Application, China New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 40. Japan New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 41. by Type, Japan New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 42. by Application, Japan New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 43. South Korea New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 44. by Type, South Korea New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 45. by Application, South Korea New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 46. Southeast Asia New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 47. by Type, Southeast Asia New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 48. by Application, Southeast Asia New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 49. India New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 50. by Type, India New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 51. by Application, India New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 52. Middle East & Africa New Molecular Entity (NME) Drug Consumption Value, 2021-2032, US$ Million
 Figure 53. by Type, Middle East & Africa New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 54. by Application, Middle East & Africa New Molecular Entity (NME) Drug Consumption Value Market Share, 2025 VS 2032
 Figure 55. Research Methodology
 Figure 56. Breakdown of Primary Interviews
 Figure 57. Bottom-up Approaches
 Figure 58. Top-down Approaches

お見積>

サンプルお申込み>

今すぐ購入>

PDFダウンロード>

当社から購入のメリット
  • jiantou

    多言語（英語、日本語）のサンプル提供

  • jiantou

    プロフェッショナルな日本語翻訳を提供

  • jiantou

    請求書、クレジットカードでのお支払いが可能です

  • jiantou

    必要なチャプターやカスタマイズされたレポートの注文が可能

  • jiantou

    購入後、アナリストに直接連絡することができます

購入方法
shunxu

  • 必要な言語とバージョンのレポート選択

  • レポート要件と見積もり依頼

  • 電子メールによる注文

  • レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）

  • クレジットカード決済、オフライン振込に対応（後払い可）

※当サイトに掲載されていない海外調査報告書も当社経由でご購入いただけますので、お問い合わせください。

※市場調査レポートの購入や市場調査をご希望の場合は、実績と信頼のある株式会社市場調査センターにお任せください。

*フォーチュン500企業は当社と緊密な協力関係を確立しています

クライアント様（例）
ご利用ガイド
利用規約よくあるご質問プライバシーポリシー支払い方法と購入ガイド
お電話でのお問い合わせ
email050-5840-2692 日本
email0081-50-5840-2692 グローバル
9:00-18:00 (土日・祝日を除く)
底部logo
Copyright 2016-2026 Global Reports著作権所有